Benzinga | Jan 26, 2022 04:16PM EST

Cue Biopharma Reports Two Objective Responses In First Interim Update From Dose Escalation Portion Of Ongoing Phase 1 Combination Study Of CUE-101 And KEYTRUDA In First Line Patients With HPV+ Recurrent/Metastatic Head And Neck Cancer

* Early data in the combination study of CUE-101 and KEYTRUDA(r) (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in the 2mg/kg and RP2D 4mg/kg cohorts, two have partial responses (1 confirmed and 1 unconfirmed) and two are manifesting reductions in target lesions

* Updated CUE-101 monotherapy data further enhances confidence in potential as single agent therapeutic with 50% clinical benefit rate reported to date in RP2D (4mg/kg) expansion monotherapy trial and an emerging enhanced overall survival rate that supports the premise that CUE-101 selectively stimulates cancer-relevant CD8+ T cells